- Conditions
- Bacterial Sepsis
- Interventions
- CPG 7909, J5-OMP Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 680
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
- Drug
- Lead sponsor
- Seattle Project Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
- Conditions
- HIV Infections
- Interventions
- rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2009
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
- Conditions
- Hookworm Infections
- Interventions
- Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum
- Biological · Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Healthy Volunteers
- Interventions
- AdCOVID, Placebo
- Biological · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Hialeah, Florida • Melbourne, Florida • Peoria, Illinois + 3 more
- Conditions
- HIV Infections
- Interventions
- ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Haemophilus Influenzae Type b, Neisseria Meningitidis
- Interventions
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 15 Months
- Enrollment
- 4,441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
- Conditions
- Influenza, Human
- Interventions
- F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH, F2H23H/DL001Z, FDQ23A-NH (Flu D-QIV), GSK5800544A, Flu D-TIV, F2H23A/DL001Z-NH, F2H23G/DL001Z, Fluzone HD Quadrivalent, Fluzone HD
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 845 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 18
- States / cities
- Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- RSVt Vaccine, Control Group
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Norfolk, Nebraska • Omaha, Nebraska
- Conditions
- COVID-19
- Interventions
- Licensed or EUA SARS-CoV-2 vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
- Conditions
- Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
- Interventions
- Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
- Biological · Drug
- Lead sponsor
- USDA, Western Human Nutrition Research Center
- Federal
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Infections, Meningococcal
- Interventions
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 3,657 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
- Conditions
- SARS-CoV2, COVID-19
- Interventions
- VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 145
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
- Conditions
- Gastroenteritis
- Interventions
- NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
- Conditions
- Lyme Disease
- Interventions
- mRNA-1975, mRNA-1982, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 807 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Milford, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 17 more
- Conditions
- SARS
- Interventions
- Aluminum hydroxide adjuvant (Alhydrogel®), Phosphate buffered saline Placebo, Recombinant S protein SARS vaccine
- Drug · Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- VGX 3100, Placebo, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Eculizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
- Conditions
- West Nile Fever
- Interventions
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
- Conditions
- Healthy
- Interventions
- RSV Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
- Conditions
- Language Development, Premature Infant, Neurodevelopmental Outcomes
- Interventions
- Know Your Baby Language Curriculum, Reading Aloud Language Curriculum, Sing A Long Language Curriculum, Mimicking First Sounds Language Curriculum, Language Games and Narrating Your Day Language Curriculum, Feeding Safety, Car Seat Safety, Bath Safety, Back to Sleep/SIDS prevention, Taking a Temperature and Signs of Infection, Infection Control Measures and Vaccine Information
- Other
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 23 Weeks to 32 Weeks
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Pneumococcal Immunization
- Interventions
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 1,714 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 66
- States / cities
- Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
- Conditions
- Herpes Zoster
- Interventions
- HZ/su vaccine GSK1437173A, Prevenar13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 913 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
- Conditions
- Influenza
- Interventions
- MEDI3414 [Influenza A(H1N1) live attenuated, intranasal], Placebo
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Sacramento, California • San Diego, California + 13 more